These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An update on the management of urinary tract infections in the era of antimicrobial resistance. Bader MS; Loeb M; Brooks AA Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137 [TBL] [Abstract][Full Text] [Related]
4. Novel Antibiotics in the Treatment of Urinary Tract Infections. Naber KG; Wagenlehner FME Eur Urol Focus; 2019 Jan; 5(1):10-12. PubMed ID: 30555037 [TBL] [Abstract][Full Text] [Related]
5. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. D'Angelo RG; Johnson JK; Bork JT; Heil EL Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857 [TBL] [Abstract][Full Text] [Related]
6. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis? Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676 [TBL] [Abstract][Full Text] [Related]
7. Current guidelines for the treatment of severe pneumonia and sepsis. Bodmann KF Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664 [TBL] [Abstract][Full Text] [Related]
8. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M; Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692 [TBL] [Abstract][Full Text] [Related]
9. Antibiotic use in neonatal sepsis. Yurdakök M Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468 [TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
11. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae. de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927 [TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240 [TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Liscio JL; Mahoney MV; Hirsch EB Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Berg ML; Crank CW; Philbrick AH; Hayden MK Ann Pharmacother; 2008 Feb; 42(2):207-12. PubMed ID: 18230703 [TBL] [Abstract][Full Text] [Related]
15. [Broad-spectrum beta-lactamases in Gram-negative bacteria]. Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis. Wagenlehner FM; Weidner W; Naber KG Clin Pharmacokinet; 2007; 46(4):291-305. PubMed ID: 17375981 [TBL] [Abstract][Full Text] [Related]
17. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Carson C; Naber KG Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349 [TBL] [Abstract][Full Text] [Related]
18. Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis. Rottier WC; Bamberg YR; Dorigo-Zetsma JW; van der Linden PD; Ammerlaan HS; Bonten MJ Clin Infect Dis; 2015 Jun; 60(11):1622-30. PubMed ID: 25694654 [TBL] [Abstract][Full Text] [Related]
19. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria]. Probst-Kepper M; Geginat G Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899 [TBL] [Abstract][Full Text] [Related]
20. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. Taneja N; Rao P; Arora J; Dogra A Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]